Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Hachulla

Showing results (481-490 of 506) with videos related to

Pageof 51
Sort By:
RMD Open|November 1, 2022
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)Jacques-Eric Gottenberg, Aurore Chaudier, Yves Allenbach, et al.
The Lancet. Rheumatology|January 23, 2024
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational studyAnne Murarasu, Gaëlle Guettrot-Imbert, Véronique Le Guern, et al.
Annals of the Rheumatic Diseases|April 11, 2019
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort studyMuriel Elhai, Marouane Boubaya, Oliver Distler, et al.
Journal of the American Academy of Dermatology|April 4, 2020
Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancyGrégoire Monseau, Océane Landon-Cardinal, Werner Stenzel, et al.
Annals of the Rheumatic Diseases|June 17, 2010
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnthony J Tyndall, Bettina Bannert, Madelon Vonk, et al.
Ebiomedicine|April 3, 2026
Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus casesMaud Tusseau, Samira Khaldi-Plassart, Audrey Labalme, et al.
Annals of the Rheumatic Diseases|March 19, 2017
Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosisChikashi Terao, Takahisa Kawaguchi, Philippe Dieude, et al.
The Lancet. Rheumatology|June 15, 2024
Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countriesEleana Bolla, Anne Grete Semb, Anne M Kerola, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
RMD Open|September 13, 2022
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registrySu-Ann Yeoh, Milena Gianfrancesco, Saskia Lawson-Tovey, et al.
Pageof 51

Showing results (481-490 of 506) with videos related to

Sort By:
Pageof 51
RMD Open|November 1, 2022
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)Jacques-Eric Gottenberg, Aurore Chaudier, Yves Allenbach, et al.
The Lancet. Rheumatology|January 23, 2024
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational studyAnne Murarasu, Gaëlle Guettrot-Imbert, Véronique Le Guern, et al.
Annals of the Rheumatic Diseases|April 11, 2019
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort studyMuriel Elhai, Marouane Boubaya, Oliver Distler, et al.
Journal of the American Academy of Dermatology|April 4, 2020
Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancyGrégoire Monseau, Océane Landon-Cardinal, Werner Stenzel, et al.
Annals of the Rheumatic Diseases|June 17, 2010
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnthony J Tyndall, Bettina Bannert, Madelon Vonk, et al.
Ebiomedicine|April 3, 2026
Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus casesMaud Tusseau, Samira Khaldi-Plassart, Audrey Labalme, et al.
Annals of the Rheumatic Diseases|March 19, 2017
Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosisChikashi Terao, Takahisa Kawaguchi, Philippe Dieude, et al.
The Lancet. Rheumatology|June 15, 2024
Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countriesEleana Bolla, Anne Grete Semb, Anne M Kerola, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
RMD Open|September 13, 2022
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registrySu-Ann Yeoh, Milena Gianfrancesco, Saskia Lawson-Tovey, et al.
Pageof 51